Povetacicept, a human TACI–Fc fusion protein engineered for dual APRIL/BAFF inhibition, has been studied in patients with IgAN, primary membranous nephropathy (MN), and lupus nephritis. Here, TNFRSF13B is linked to lupus nephritis.